NCT03964051View on ClinicalTrials.gov

Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).

PHASE4TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions

Food Allergy

Interventions

DRUG

Omalizumab Injection

Omalizumab 300 mg for subcutaneous injection

Trial Locations (1)

5000

Odense Research Center for Anaphylaxis, Allergy Center, Odense C

Sponsors

Collaborators (1)

Miltenyi Biomedicine GmbH

All Listed Sponsors

collaborator

Miltenyi Biomedicine GmbH

INDUSTRY

lead

Carsten Bindslev-Jensen

OTHER